
hVIVO - Positive topline results from client Phase 2b field study
HVO Mon, 30 Jun 2025, 14:00 BST
hVIVO's Chief Scientific Officer, Dr Andrew Catchpole, discusses Cidara Therapeutics positive topline results from their Phase 2b field study, for which hVIVO recruited participants and performed the virology and immunology laboratory services. The study was to determine the efficacy of Cidara's drug-Fc conjugate, CD388, which is designed as a non-vaccine preventative of seasonal influenza.

Dr. Andrew Catchpole
Chief Scientific Officer, hVIVO
Dr. Andrew Catchpole, Chief Scientific Officer, hVIVO
Mon, 30 Jun 2025, 2:00pm BST
Adam French, VP, Clinical Operations, hVIVO
Fri, 24 Jan 2025, 7:00am GMT
Dr Yamin ‘Mo’ Khan, Chief Executive Officer, hVIVO
Wed, 17 Jul 2024, 10:00am BST
Management Team, hVIVO plc
Fri, 22 Dec 2023, 11:09am GMT
Dr Yamin ‘Mo’ Khan, Chief Executive Officer, hVIVO
Wed, 2 Nov 2022, 9:30am GMT
Dr Yamin ‘Mo’ Khan, Chief Executive Officer, hVIVO
Fri, 28 Oct 2022, 1:33pm BST